IL18 and systemic-onset juvenile idiopathic arthritis: Moreover, monoclonal antibodies targeting IL-18, such as GSK-1070806 and camoteskimab, are currently under development for conditions like atopic dermatitis and Still’s disease, and may hold potential for therapeutic evaluation in SLE.